Transcranial alternating current stimulation (tACS) at gamma frequency: an up-and-coming tool to modify the progression of Alzheimer's Disease

The last decades have witnessed huge efforts devoted to deciphering the pathological mechanisms underlying Alzheimer's Disease (AD) and to testing new drugs, with the recent FDA approval of two anti-amyloid monoclonal antibodies for AD treatment. Beyond these drug-based experimentations, a numb...

Full description

Saved in:
Bibliographic Details
Published in:Translational neurodegeneration 2024-06, Vol.13 (1), p.33-34, Article 33
Main Authors: De Paolis, Maria Luisa, Paoletti, Ilaria, Zaccone, Claudio, Capone, Fioravante, D'Amelio, Marcello, Krashia, Paraskevi
Format: Article
Language:English
Subjects:
Alzheimer Disease - therapy
Alzheimer’s disease
Animals
Brain waves
Disease Progression
Gamma oscillations
Gamma Rhythm - physiology
Humans
Mild cognitive impairment
Neuromodulation
Non-invasive brain stimulation
Review
Transcranial Direct Current Stimulation - methods
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The last decades have witnessed huge efforts devoted to deciphering the pathological mechanisms underlying Alzheimer's Disease (AD) and to testing new drugs, with the recent FDA approval of two anti-amyloid monoclonal antibodies for AD treatment. Beyond these drug-based experimentations, a number of pre-clinical and clinical trials are exploring the benefits of alternative treatments, such as non-invasive stimulation techniques on AD neuropathology and symptoms. Among the different non-invasive brain stimulation approaches, transcranial alternating current stimulation (tACS) is gaining particular attention due to its ability to externally control gamma oscillations. Here, we outline the current knowledge concerning the clinical efficacy, safety, ease-of-use and cost-effectiveness of tACS on early and advanced AD, applied specifically at 40 Hz frequency, and also summarise pre-clinical results on validated models of AD and ongoing patient-centred trials.
ISSN:2047-9158
2047-9158
DOI:10.1186/s40035-024-00423-y